Children

Clinical trials have recently shown that treatment of HCV infection in children under the age of 18 years is safe and effective. Treatment regimens that have been evaluated in children aged under 18 years include sofosbuvir plus velpatasvir, glecaprevir plus pibrentasvir, and sofosbuvir plus ledipasvir (for Gt 1 HCV). [51-56] 

HCV treatments listed on the PBS can now be prescribed to children under the age of 18 years. Children aged under 18 years should be referred to a paediatrician who is experienced in the treatment of HCV for discussion about therapy. A document providing specific guidance on the treatment of HCV infection in children under the age of 18 years is in development and will be made available on the GESA and Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine websites.